A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development

Toxicological Sciences

Volumn 136, Issue 1, 2013, Pages 216-241

  Morgan, Ryan E ^a   van Staden, Carlo J ^a   Chen, Yuan ^a   Kalyanaraman, Natarajan ^a   Kalanzi, Jackson ^a   Dunn II, Robert T ^a   Afshari, Cynthia A ^a   Hamadeh, Hisham K ^a  

^a AMGEN INC   (United States)

Author keywords

ATP binding cassette transporter; Bile acid; Bile salt export pump; Drug induced liver injury.; Multidrug resistance associated protein; Transporter

Indexed keywords

BILE SALT EXPORT PUMP; CARRIER PROTEIN; CLOFIBRATE; CYCLOSPORIN A; DEFERASIROX; DICLOXACILLIN; FENOFIBRATE; FUSIDIC ACID; KETOCONAZOLE; LAPATINIB; LOPINAVIR; MIFEPRISTONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; OCTREOTIDE; PACLITAXEL; PAZOPANIB; PIOGLITAZONE; POSACONAZOLE; RIFAPENTINE; RITONAVIR; TOLCAPONE; TRANILAST; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERLUKAST;

ARTICLE; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DRUG POTENCY; HOMEOSTASIS; IC 50; IN VITRO STUDY; MEMBRANE VESICLE; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RISK ASSESSMENT; STEADY STATE; TOXIC HEPATITIS;

ATP-BINDING CASSETTE TRANSPORTER; BILE ACID; BILE SALT EXPORT PUMP; DRUG-INDUCED LIVER INJURY.; MULTIDRUG RESISTANCE- ASSOCIATED PROTEIN; TRANSPORTER;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CLUSTER ANALYSIS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIVER; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; TOXICITY TESTS;

EID: 84887898959     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft176     Document Type: Article

References (40)

1. Amacher, D. E. (2012). The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 8, 335-347.
2. Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J. Clin. Pharmacol. 43, 443-469.
3. Corsini, A., Ganey, P., Ju, C., Kaplowitz, N., Pessayre, D., Roth, R., Watkins, P. B., Albassam, M., Liu, B., Stancic, S., et al. (2012). Current challenges and controversies in drug-induced liver injury. Drug Saf. 35, 1099-1117.
4. Daly, A. K. (2010). Drug-induced liver injury: Past, present and future. Pharmacogenomics 11, 607-611.
5. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2012). In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130-138.
6. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., and Meier, P. J. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231.
7. Feng, B., Xu, J. J., Bi, Y. A., Mireles, R., Davidson, R., Duignan, D. B., Campbell, S., Kostrubsky, V. E., Dunn, M. C., Smith, A. R., et al. (2009). Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci. 108, 492-500.
8. Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. (2001). Cholestatic potential of troglitazone as a possible factor contributing to troglitazoneinduced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627-635.
9. Gerk, P. M., Li, W., and Vore, M. (2004). Estradiol 3-glucuronide is transported by the multidrug resistance-associated protein 2 but does not activate the allosteric site bound by estradiol 17-glucuronide. Drug Metab. Dispos. 32, 1139-1145.
10. Hamadeh, H. K., Todd, M., Healy, L., Meyer, J. T., Kwok, A. M., Higgins, M., and Afshari, C. A. (2010). Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors. Chem. Res. Toxicol. 23, 1025-1033.
11. Heredi-Szabo, K., Kis, E., Molnar, E., Gyorfi, A., and Krajcsi, P. (2008). Characterization of 5(6)-carboxy-2,'7'-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4. J. Biomol. Screen. 13, 295-301.
12. Keppler, D. (2011a). Cholestasis and the role of basolateral efflux pumps. Z. Gastroenterol. 49, 1553-1557.
13. Keppler, D. (2011b). Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy. Handbook Exp. Pharmacol. 201, 299-323. doi:10.1007/978-3-642-14541-4_8.
14. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451-459.
15. Kostrubsky, V. E., Strom, S. C., Hanson, J., Urda, E., Rose, K., Burliegh, J., Zocharski, P., Cai, H., Sinclair, J. F., and Sahi, J. (2003). Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. 76, 220-228.
16. Kubitz, R., Dröge, C., Stindt, J., Weissenberger, K., and Häussinger, D. (2012). The bile salt export pump (BSEP) in health and disease. Clin. Res. Hepatol. Gastroenterol. 36, 536-553.
17. Letourneau, I. J., Bowers, R. J., Deeley, R. G., and Cole, S. P. (2005). Limited modulation of the transport activity of the human multidrug resistance proteins MRP1, MRP2 and MRP3 by nicotine glucuronide metabolites. Toxicol. Lett. 157, 9-19.
18. Li, F., Patterson, A. D., Krausz, K. W., Tanaka, N., and Gonzalez, F. J. (2012). Metabolomics reveals an essential role for peroxisome proliferator-activated receptor a in bile acid homeostasis. J. Lipid Res. 53, 1625-1635.
19. Lundell, K., and Wikvall, K. (2008). Species-specific and age-dependent bile acid composition: Aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr. Drug Metab. 9, 323-331.
20. Masubuchi, Y. (2006). Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metab. Pharmacokinet. 21, 347-356.
21. Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W. Jr, Lightfoot-Dunn, R., and Hamadeh, H. K. (2010). Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118, 485-500.
22. National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.). (2011). Guide for the Care and Use of Laboratory Animals, Vol. xxv, 220 pp. National Academies Press, Washington, DC. http://www.ncbi.nlm.nih.gov/books/NBK54050/
23. Nies, A. T., and Keppler, D. (2007). The apical conjugate efflux pump ABCC2 (MRP2). Pflugers. Arch. 453, 643-659.
24. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
25. Palmeira, C. M., and Rolo, A. P. (2004). Mitochondrially-mediated toxicity of bile acids. Toxicology 203, 1-15.
26. Pedersen, J. M., Matsson, P., Bergström, C. A., Norinder, U., Hoogstraate, J., and Artursson, P. (2008). Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 51, 3275-3287.
27. Rogue, A., Spire, C., Brun, M., Claude, N., and Guillouzo, A. (2010). Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res. 2010, 325183.
28. Rolo, A. P., Palmeira, C. M., Holy, J. M., and Wallace, K. B. (2004). Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: The switch between apoptosis and necrosis. Toxicol. Sci. 79, 196-204.
29. Rolo, A. P., Palmeira, C. M., and Wallace, K. B. (2003). Mitochondrially mediated synergistic cell killing by bile acids. Biochim. Biophys. Acta 1637, 127-132.
30. Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., and Aleo, M. D. (2011). Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24, 1345-1410.
31. Stieger, B. (2010). Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab. Rev. 42, 437-445.
32. Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., and Meier, P. J. (2000). Drug-and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118, 422-430.
33. Stieger, B., Meier, Y., and Meier, P. J. (2007). The bile salt export pump. Pflugers. Arch. 453, 611-620.
34. Stine, J. G., and Lewis, J. H. (2011). Drug-induced liver injury: A summary of recent advances. Expert Opin. Drug Metab. Toxicol. 7, 875-890.
35. Trauner, M., and Boyer, J. L. (2003). Bile salt transporters: Molecular characterization, function, and regulation. Physiol. Rev. 83, 633-671.
36. Tujios, S., and Fontana, R. J. (2011). Mechanisms of drug-induced liver injury: From bedside to bench. Nat. Rev. Gastroenterol. Hepatol. 8, 202-211.
37. van Staden, C. J., Morgan, R. E., Ramachandran, B., Chen, Y., Lee, P. H., and Hamadeh, H. K. (2012). Membrane vesicle ABC transporter assays for drug safety assessment. Curr. Protoc. Toxicol. Chapter 23, Unit 23.5.
38. Zhou, S. F., Wang, L. L., Di, Y. M., Xue, C. C., Duan, W., Li, C. G., and Li, Y. (2008). Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 15, 1981-2039.
39. Zollner, G., Marschall, H. U., Wagner, M., and Trauner, M. (2006). Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251.
40. Zollner, G., Wagner, M., and Trauner, M. (2010). Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol. Ther. 126, 228-243.